Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 42, Issue 1-2, 2001, Pages 41-56

  Uckun, F M ^a   Pallisgaard, N ^a   Hokland, P ^a   Navara, C ^a   Narla, R ^a   Gaynon, P S ^a   Sather, H ^a   Heerema, N ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

ALL; Minimal residual disease; MRD; Rapid early response; Remission; TEL AML1

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; COMPLEMENTARY DNA; CORE BINDING FACTOR; DNA BINDING PROTEIN; HYBRID PROTEIN; MESSENGER RNA; PREDNISONE; RNA; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CELL STRUCTURE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 12P; CHROMOSOME 21; CHROMOSOME 6Q; CHROMOSOME DELETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIPLOIDY; DRUG EFFICACY; FEMALE; FREQUENCY ANALYSIS; FUSION GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

EID: 0034920241     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097675     Document Type: Article

References (50)

1. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms
2. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
3. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
4. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13)
5. Translocation (12;22)(p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11
6. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia
7. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
8. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in remission and predict clinical relapse
9. The role of chromosome translocations in leukemogenesis
10. Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations
11. Transformation properties of the ETO gene, fusion partners in t(8;21) leukemias
12. Core-binding factor: A central player in hematopoiesis and leukemia
13. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
14. High frequency of t(12;21) in childhood B-lineageacute lymphoblastic leukemia
15. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
16. TEL/AML1 positivity in childhood ALL: Average or better prognosis?
17. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediatric Oncology Group study
18. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
19. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia
20. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero
21. Prenatal origin of acute lymphoblastic leukemia in children
22. A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL)
23. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group Study
24. Clinical Significance of Philadelphia Chromosome-Positive Pediatric Acute Lymphoblastic Leukemia in the Context of Contemporary Intensive Therapies: A Report from the Children's Cancer Group
25. Clinical Significance of Translocation t(1;19) in Childhood Acute Lymphoblastic Leukemia in the Context of Contemporary Therapies: A Report From The Children's Cancer Group
26. Treatment Outcome and Prognostic Factors for Infants with Acute Lymphoblastic Leukemia Treated on Consecutive Trials of the Children's Cancer Group
27. Chromosome arm 12p abnormalities in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
28. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
29. Lineage specificity of chromosomal abnormalities in immunologically classified newly diagnosed childhood acute lymphoblastic leukemia patients
30. Expression of BCR-ABL, E2A-PBX1 and MLL-AF4 Fusion Transcripts in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Initiative
31. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
32. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript
33. Early response to therapy and outcome in childhood acute lymphoblastic leukemia
34. TEL-AML1 translocations, TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines
35. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia
36. Acute lymphoblastic leukemia of childhood: Identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1
37. TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia
38. Oligomerization of the ABL tyrosine kinase by the ets protein TEL in human leukemia
39. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion
40. Current status of cytogenetic research in childhood acute lymphoblastic leukemia
41. Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 Among Children With Acute Lymphoblastic Leukemia and High Hyperdiploidy (>50 Chromosomes)
42. 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia
43. Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia
44. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood
45. KIP1
46. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies
47. Molecular characterization of 12p abnormalities in hematologic malignancies: Deletion of KIP1, rearrangement of TEL, and amplification of CCND2
48. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome